Company · SCTX
Scribe Therapeutics Inc.
Name as listed on its exchange; filed with the SEC as Scribe Therapeutics, Inc.
Nasdaq's symbol directory lists SCTX on Nasdaq as “Scribe Therapeutics Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders bought on 6 occasions ($56.3M); 5 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Behzad Aghazadeh bought $36.3M
- ORBIMED ADVISORS LLC bought $15.0M
- AH Bio Fund II, L.P. bought $5.0M
- Lucas Svetlana, Chief Business Officer bought $45K
- Parrot David, Chief Financial Officer bought $40K
Every trade (6)
- BUYBehzad Aghazadeh bought $144K
- BUYORBIMED ADVISORS LLC bought $15.0M
- BUYAH Bio Fund II, L.P. bought $5.0M
- BUYBehzad Aghazadeh bought $36.1M
- BUYLucas Svetlana, Chief Business Officer bought $45K
- BUYParrot David, Chief Financial Officer bought $40K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- AH Bio Fund II, L.P. 16.3%
- RA Capital Management, L.P. 9.6%
- Avoro Capital Advisors LLC 13.78%
- ELI LILLY & Co 7.3%
- ORBIMED ADVISORS LLC 7.2%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 12, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.